NRAS and acute myeloid leukemia: Additionally, ABD957, a strong and selective covalent inhibitor of the ABHD17A/B/C, inhibits NRAS depalmitoylation in AML cells, resulting in suppressed NRAS signaling and the development of NRAS‐mutant AML [132] (Table 1).